The Relative Strength (RS) Rating for ACADIA Pharmaceuticals climbed into a higher percentile Monday, as it got a lift from 68 to 76.
This unique rating measures technical performance by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Decades of market research shows that the stocks that go on to make the biggest gains often have an 80 or better RS Rating in the early stages of their moves. See if ACADIA Pharmaceuticals can continue to show renewed price strength and hit that benchmark.
Can You Really Time The Stock Market?
ACADIA Pharmaceuticals is not currently showing a potential entry point. See if the stock goes on to form a base that could kick off a new climb.
While revenue growth fell last quarter from 18% to 12%, earnings-per-share grew 207%, up from 0% in the prior report.
The company earns the No. 15 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
